Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HPV-16/18 Vaccine (Walrinvax) in Healthy Females
NCT02733068Phase 3Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of Walrinvax in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Started Nov 2014; status: completed.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02733068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733068.